LJI scientists harness ‘helper’ T cells to treat tumors
New preclinical research shows researchers how to give CD4+ and CD8+ T cells more cancer-fighting power
New LJI research has major implications for controlling T cell activity
How a supposed "nuclear" receptor makes TCR signaling possible
LJI scientists solve the mystery of why OGT enzyme is critical for cell survival
LA JOLLA, CA — Researchers at La Jolla Institute for Immunology (LJI) have at last uncovered how an enzyme called
On the trail of missing genes and cancer clues
LJI scientists connect TET loss of function to missing genes in embryonic stem cells
Get to know Ferhat Ay, Ph.D., the chromosome cartographer
How computational biology is propelling the field of immunology
Investigating cancer drug toxicity leads to a critical discovery
LA JOLLA—It’s not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started
Strange DNA structures may drive cancer development
LJI researchers shed light on the role of TET enzymes in genomic stability and cancers
Six LJI scientists named “Highly Cited Researchers”
The international recognition reflects how LJI research is valued by scientific peers
Immune cells can detect cancer
Now we can see what they see — and help
Preparing T cells for the long haul
New LJI research could keep cancer-fighting T cells from burning out before the job is done
Hard-working enzyme keeps immune cells in line
LJI scientists develop new tool for understanding enzymatic activity linked to blood cancers and heart disease
Many cancer patients may need a sequential one-two punch of immunotherapies
Treating patients with anti-CTLA4 therapies prior to anti-PD1 treatment may be a promising strategy